• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Novo Nordisk

280.30 DKK

-1.86 %

1,053 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.86 %
-6.32 %
+13.46 %
-13.82 %
-11.41 %
-45.70 %
-49.24 %
+7.91 %
+22,414.06 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.25T DKK
Turnover
1.06B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
12.16
Dividend yield-%
4.17 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Forum discussions
I don’t know if this deviates too much from the topic, but at the risk of addressing a sensitive subject, I would like to highlight one perspective that often remains completely in the dark: namely, the massive potential environmental impact of GLP-1 drugs. In nutritional and environmental...
6/5/2026, 5:43 AM
by Timo Huhtamäki
64
The market is currently paying far too much attention to who has the best percentages in clinical trials. In 5 years, it won’t matter whether the figure is 18%, 23%, or 28%. For the consumer, price will be the deciding factor and other things will be secondary. And since patents ...
6/6/2026, 7:27 PM
by JNivala
61
Yep, I’ve been pondering the same thing—why hasn’t this price collapse affected Eli Lilly’s valuation multiples? To a layman’s eye, the new drugs don’t seem so much better that I’d pay significantly more for them. Then again, I’m not the target audience and I don’t understand anything...
6/7/2026, 8:47 AM
by samamies
23
https://www.marketwatch.com/story/the-wegovy-pill-is-still-dominating-the-glp-1-pill-market-f7add507?mod=home_lead Pill sales have gotten off to a nice start. Eli Lilly’s pill sales launched much more sluggishly.
6/8/2026, 6:44 AM
by Kryptoniitti
17
Manufacturing semaglutide is a demanding process, so as I understand it, its price will not drop to the level of aspirin anytime soon. Novo holds a competitive advantage in manufacturing processes and production machinery, allowing them to generate strong profits for a long time—...
6/7/2026, 4:08 PM
by Kari Kokkonen
13
In India, the Semaglutide patent expired this year; now, the prices of generic drugs are €14–19/month instead of the former €75–93, and prices are expected to drop further as competition increases. Yle Uutiset – 16 Apr 26 ”Emme osaa lopettaa syömistä”, sanoo intialaisnainen – halpa...
6/7/2026, 4:37 PM
by cicada
9
Yeah, it’s true that this won’t drop to “3e/month” prices like Primaspn/statins, but the percentage drop from current prices will be very large. And all of that will come straight off the bottom line.
6/7/2026, 5:34 PM
by JNivala
8
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5/8
2026

Interim report Q2'26

4/11
2026

Interim report Q3'26

Regulatory press releaseyesterday

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release6/11/2026, 3:30 PM

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Novo Nordisk
Press release6/11/2026, 3:02 PM

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/8/2026, 12:09 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release6/3/2026, 6:00 AM

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk
Regulatory press release6/1/2026, 11:16 AM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release5/26/2026, 2:16 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release5/26/2026, 8:41 AM

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Novo Nordisk
Regulatory press release5/22/2026, 5:30 PM

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Novo Nordisk
Regulatory press release5/22/2026, 1:08 PM

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

Novo Nordisk
Press release5/19/2026, 12:00 PM

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk
Regulatory press release5/18/2026, 1:38 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release5/13/2026, 6:00 AM

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Novo Nordisk
Regulatory press release5/12/2026, 2:48 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk
Press release5/12/2026, 10:25 AM

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

Novo Nordisk
Press release5/12/2026, 6:00 AM

Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity

Novo Nordisk
Regulatory press release5/6/2026, 5:31 AM

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026

Novo Nordisk
Regulatory press release5/5/2026, 10:43 AM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release4/28/2026, 12:00 PM

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

Novo Nordisk
Regulatory press release4/27/2026, 8:56 AM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk